Krystal Biotech (KRYS) announced that Japan's Ministry of Health, Labour and Welfare granted marketing authorization to VYJUVEK for the treatment of wounds in patients with dystrophic epidermolysis bullosa, starting from birth. VYJUVEK is the first genetic medicine approved in Japan for the treatment of DEB. The company said timing for availability of VYJUVEK in Japan will depend on completion of reimbursement procedures currently underway. The company expects to launch in Japan by the end of the current year.
VYJUVEK was previously approved by the Food and Drug Administration in the United States in May 2023 and by the European Commission in April 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.